venetoclax plus obinutuzumab in ckt cll: analysis from the cll14 trial
Published 5 years ago • 264 plays • Length 1:24Download video MP4
Download video MP3
Similar videos
-
5:54
cll14: venetoclax plus obinutuzumab for cll
-
1:43
six-year update from cll14: fixed-duration venetoclax obinutuzumab for previously untreated cll
-
1:25
the potential of triplet regimens combining btkis with venetoclax and obinutuzumab in cll
-
1:23
interim analysis of the flair study: efficacy of ibrutinib plus venetoclax in ighv unmutated cll
-
3:22
combining venetoclax and obinutuzumab in the treatment of cll
-
2:03
venetoclax and obinutuzumab combination therapy for cll
-
5:00
venetoclax-obinutuzumab is superior to chemoimmunotherapy in frontline cll: updates from gaia/cll13
-
3:09
bleximenib combined with venetoclax and azacitidine in r/r aml with kmt2a or npm1 alterations
-
3:06
mechanism of action of venetoclax (abt-199) and its side effects
-
2:49
results from the phase iii echo trial of acalabrutinib plus br in mcl
-
1:17
the evolution of frontline treatment for cll: from chemoimmunotherapy to targeted agents
-
3:15
overview of a phase ib study of venetoclax and obinutuzumab in cll
-
0:48
venetoclax and obinutuzumab for cll
-
1:59
acalabrutinib, venetoclax and obinutuzumab upfront for cll
-
2:45
the addition of venetoclax to hmas for the treatment of cmml: a retrospective psm analysis
-
2:11
atezolizumab with venetoclax and obinutuzumab in patients with cll
-
1:00
reveng: venetoclax and obinutuzumab in cll
-
2:08
the role of venetoclax in the treatment of cll
-
2:00
obinutuzumab, ibrutinib, and venetoclax in high-risk cll: the cll2-give and cll13 trials
-
2:06
venetoclax and ibrutinib for r/r cll: analysis from the vision/ho141 trial
-
4:31
sequence of administration of ibrutinib with obinutuzumab in r/r cll patients